Skip to main content
JACC Case Reports logoLink to JACC Case Reports
editorial
. 2026 Oct 21;31(42):110666. doi: 10.1016/j.jaccas.2026.110666

Transcatheter Salvage of the Ascending Aorta

Current Strategies, Challenges, and Future Perspectives

Edoardo Zancanaro a,∗, Thomas Modine b, Tommaso Hinna Danesi a
PMCID: PMC13699031  PMID: 42910799

Corresponding Author

graphic file with name ga1.webp

Key Words: coronary protection, endovascular repair, penetrating atherosclerotic ulcer, pseudoaneurysm, structural intervention, type IA endoleak


The case reported by Kaleeny et al1 in this issue of JACC: Case Reports underscores a widening therapeutic gap. The ascending aorta remains one of the last territories of aortic disease in which open surgery retains a near monopoly. Both the 2022 American College of Cardiology/American Heart Association and the 2024 European Society of Cardiology guidelines recommend urgent open repair for penetrating atherosclerotic ulcer (PAU) involving the ascending aorta, particularly when complicated by rupture.2,3 Yet, PAU often occurs in older, frail, multimorbid patients, precisely those least able to tolerate sternotomy, cardiopulmonary bypass, and circulatory arrest. When surgery is prohibitive, treatment options have often narrowed to individualized off-label endovascular therapy or palliation. Into that gap, a small but growing literature on endovascular ascending repair has emerged, initially by repurposing devices designed for other aortic segments and, more recently, through dedicated ascending platforms and structural-heart techniques.4,5

Kaleeny et al1 push that envelope further. One month after emergency endovascular repair of a ruptured ascending PAU, their 75-year-old patient (EuroSCORE II 52.5%; Clinical Frailty Scale 6) represented with a late type IA endoleak and an 89-mm pseudoaneurysm. Rather than accept palliation and after renewed Heart Team discussion in accordance with the patient's preference, the team designed a staged, fully percutaneous salvage. A transcatheter aortic valve provided a protective scaffold at the root; an atrial septal defect occluder was jailed across much of the pseudoaneurysm neck; and, at a second procedure, a cribriform patent foramen ovale occluder, coils, and thrombin completed exclusion of the sac. Complete sealing was documented and remained stable at 1 year.

The Heart Team discipline, meticulous preprocedural computed tomographic planning, measurement of coronary heights and sinotubular dimensions, annular sizing, controlled prosthesis oversizing, and a device sequence deliberately choreographed to preserve valve function and coronary perfusion reflect genuine structural expertise. Above all, the report vividly demonstrates how the structural operator's toolbox—valves, occluders, coils, and thrombin, can be repurposed when no dedicated rescue device exists. That ingenuity matters, but so does the context: patient preference can appropriately influence decision-making when a guideline-supported open repair is not feasible and no established transcatheter pathway exists.

The most instructive lesson may be how the complication arose in the first place. The index repair used overlapping thoracic branch endoprostheses, devices developed for thoracic aortic and arch applications, in the ascending position.6 On repeat imaging, the grafts had expanded to 50 mm, beyond their 45- to 46-mm nominal dimensions. The authors hypothesize that the resulting radial force and medial injury contributed to the proximal endoleak and pseudoaneurysm. That mechanism is plausible, but it cannot be established from a single case. The broader lesson is clearer. The ascending aorta is short, curved, highly mobile, high-flow, and immediately adjacent to the coronary ostia, aortic valve, and arch branches; it is an unforgiving environment for hardware designed for a different segment. The elegant rescue is therefore also a reminder that off-label device repurposing may carry a durability penalty that only becomes apparent after initial technical success.

The proximal seal is especially constrained: deployment too low can obstruct a coronary ostium or impair valve function, whereas deployment too high shortens fixation and approaches the brachiocephalic trunk. When ostial clearance is marginal, prepositioned coronary guidewires and undeployed stents permit bailout or planned chimney stenting. A chimney, however, adds metal layers and may create gutters, deformation, thrombosis, impaired future coronary access, and uncertain durability. Fenestrated, branched, and Endo-Bentall concepts seek more anatomic preservation of coronary and supra-aortic perfusion, but remain technically demanding, anatomy-dependent, and supported mainly by early experience.5 Dedicated ascending devices therefore require short configurable lengths, conformability, precise controlled deployment, and integrated strategies for the aortic valve, both coronaries, and arch branches.4,5

The construct itself, however successful, is difficult to generalization. This was a bespoke, multidevice, off-label solution executed by an expert team: proof of feasibility, not a reproducible protocol. One year of follow-up is encouraging but remains short for a pressurized ascending aortic pseudoaneurysm treated with occluders, coils, and thrombin. Late device migration or embolization, coronary or valvular compromise, sac reperfusion, thrombosis, and device infection are relevant surveillance concerns. The antithrombotic strategy—aspirin monotherapy for the first month followed by lifelong rivaroxaban—also illustrates how little evidence exists to guide pharmacotherapy after such hybrid constructs.

Where does this leave us? Three priorities stand out. First, purpose-built ascending platforms must mature. The NAVIGATE registry with the Nexus Ascending Module provides important multicenter proof of concept, but remains early experience rather than definitive evidence.4 Second, dedicated strategies for proximal endoleaks and ascending pseudoaneurysms are needed; septal occluders can be ingenious rescue tools, but chronic systemic aortic loading was never their design target. Third, and most actionable now, cases like this should be captured in collaborative registries with standardized procedural definitions, device reporting, antithrombotic strategies, and imaging follow-up so that the field can move from anecdote toward evidence (Figure 1).

Figure 1.

Figure 1

Transcatheter Salvage of the Ascending Aorta

A ruptured ascending penetrating atherosclerotic ulcer in a surgically prohibitive patient was initially treated with off-label ascending thoracic endovascular aortic repair (TEVAR), followed by a proximal type IA endoleak and large pseudoaneurysm. Staged transcatheter salvage used transcatheter aortic valve implantation (TAVI) to protect the native valve and coronary ostia, an atrial septal defect (ASD) occluder across the pseudoaneurysm neck, and a patent foramen ovale (PFO) occluder with coils and thrombin to complete exclusion. Short landing zones, coronary and arch-branch preservation, and device-aorta mismatch remain central challenges.

Until those tools and that evidence arrive, the structural toolbox may remain a legitimate rescue option, in expert centers, after multidisciplinary review, for carefully selected surgically ineligible patients who understand the uncertainty.

Funding Support and Author Disclosures

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Acknowledgment

Figure 1 was created with generative artificial intelligence and reviewed by the authors for anatomical and clinical accuracy.

Footnotes

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

References

  • 1.Kaleeny K., Kamalanathan H., Lewis J., et al. Endovascular salvage of late type IA endoleak after ascending aortic TEVAR for ruptured penetrating ulcer. JACC Case Rep. 2026;31(42) doi: 10.1016/j.jaccas.2026.110003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Isselbacher E.M., Preventza O., Hamilton Black J., 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;80:e223–e393. doi: 10.1016/j.jacc.2022.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mazzolai L., Teixido-Tura G., Lanzi S., et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45:3538–3700. doi: 10.1093/eurheartj/ehae179. [DOI] [PubMed] [Google Scholar]
  • 4.Mosquera V.X., Ferreiro A., Abisi S., et al. The NAVIGATE registry: early endovascular repair of the ascending aorta with the nexus ascending module. Interdiscip Cardiovasc Thorac Surg. 2026;41 doi: 10.1093/icvts/ivag128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shehab M., Prendes C.F., Wanhainen A., et al. The Endo-Bentall procedure in the treatment of ascending aorta pathologies: a scoping review. Eur J Vasc Endovasc Surg. 2026;71:415–425. doi: 10.1016/j.ejvs.2025.07.026. [DOI] [PubMed] [Google Scholar]
  • 6.Schmid B.P., Kanamori L.R., Oden-Brunson H.V., et al. Technical considerations and contemporary literature review of the Gore Thoracic Branch Endoprosthesis. J Cardiovasc Surg. 2026;67:35–42. doi: 10.23736/S0021-9509.25.13474-5. [DOI] [PubMed] [Google Scholar]

Articles from JACC Case Reports are provided here courtesy of Elsevier

RESOURCES